Research Signal – Source date 2024-03-01
When basosquamous carcinoma, a type of skin cancer, becomes locally advanced or metastatic, treatment can be difficult to organize. The condition described in this paper is not amenable to surgery or radiotherapy by definition, yet clinicians still need to consider what treatment possibilities remain and whether one drug approach should come before another.
A paper published on March 1, 2024, brings together five real-life cases treated at the Dermato-Oncology Unit of Trieste with a review of reported treatment options. The review mentions 17 patients in total, although the supplied abstract does not make clear whether that figure includes the five Trieste cases. Its conclusions are preliminary, but it offers a possible way to think about treatment order.
Why treatment becomes difficult
The report focuses on locally advanced or metastatic basosquamous carcinoma described as not amenable to surgery or radiotherapy. That makes systemic drug treatments a central question, although the abstract also mentions combined approaches involving local treatment in some patients.
The paper’s contribution is therefore not a comparison of a single drug with a single procedure. It combines experience from five patients with treatment reports gathered from the literature. Those components provide context for possible choices, but the abstract does not supply enough patient-level detail to show how treatments were selected, how long they were used, or how outcomes differed between them.
An earlier and a subsequent drug position
The authors propose sonidegib and vismodegib as possible first-line treatments. Here, first-line means the earlier treatment position in a sequence, not a proven best choice for every patient. Both are sonic hedgehog pathway inhibitors, placing them in the same broad treatment category for the proposed initial approach.
Cemiplimab is identified as a possible second-line option. Second-line means a later treatment position when another treatment is needed; it does not by itself establish that the drug should follow an inhibitor in every case. Cemiplimab is an anti-PD-1 immune checkpoint treatment.
This ordering is the authors’ interpretation of preliminary data. The supplied abstract does not establish that one sequence produces better outcomes than another, or that the proposed order is optimal. It also does not support numerical estimates for response, survival, response duration, or adverse-event rates. Those limits prevent the paper’s abstract from being used to choose treatment for an individual patient.
How local treatments fit the reported picture
The abstract also reports chemotherapy and combined approaches involving surgery and radiotherapy as suitable in some patients. That may seem difficult to reconcile with the description of locally advanced and metastatic disease as not amenable to surgery or radiotherapy. The paper presents both points: the general treatment dilemma and selected reports in which local treatments formed part of a combined approach.
The supplied evidence does not explain the circumstances behind those uses or identify which patient characteristics made them appropriate. It is safer, therefore, to read these reports as evidence that several approaches have been attempted in selected cases, rather than as a general recommendation to return to surgery or radiotherapy.
The same caution applies to chemotherapy. Its mention shows that it has been part of the reported treatment landscape, but the abstract does not establish where it belongs in relation to hedgehog pathway inhibitors or cemiplimab, nor which patients might benefit from it.
What additional treatment options could mean for patients
If the proposed sequence proves beneficial and tolerable, patients whose advanced basosquamous carcinoma cannot be managed with surgery or radiotherapy could have a clearer route from an initial drug treatment to a subsequent option. The authors suggest sonidegib or vismodegib first, with cemiplimab as a possible later treatment.
That prospect remains conditional. Further evidence would need to show whether these treatments provide meaningful benefit, whether they are tolerable, and how their sequence should be chosen. The case series and literature review open a treatment possibility; they do not yet establish a standard pathway, a cure, longer survival, or avoidance of local treatment.
Key Sources
- Primary source: Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
DOI or Journal Page · Review or Meta-Analysis · 2024-03-01
Keep exploring